Clinical trials: Estrogen
Early Breast Cancer
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance.
- Trial name
- NCT07541079
- Testing
- Giredestrant
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Genentech, Inc.
Vaginal Dryness
Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness
Vulvovaginal irritation due to dryness is a frequent complaint among post- and some premenopausal women. International guidelines recommend non-hormonal products as first line therapy.
- Trial name
- NCT02269826
- Testing
- Vagisan® Moisturising Cream, Gynomunal® vaginal gel
- Where
- 6 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Neoplasms, Breast
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
This is a randomised, open label multicenter Phase III study comparing the efficacy of neoadjuvant lapatinib plus paclitaxel, versus trastuzumab plus paclitaxel, versus concomitant lapatinib and trastuzumab plus paclitaxel given…
- Trial name
- Neo ALTTO (NCT00553358)
- Testing
- Lapatinib, Trastuzumab, Paclitaxel
- Where
- 121 sites in Argentina, Belgium and 22 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients
The purpose of this study is to examine the immunological response rate to administration of the THERATOPE® vaccine in women with stable metastatic breast cancer who are being treated with aromatase inhibitors or Faslodex® and…
- Trial name
- NCT00046371
- Testing
- THERATOPE® vaccine
- Where
- 17 sites in United States
- Sponsor
- Oncothyreon Canada Inc.
Atrophic Vaginitis, Atrophy
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
- Conditions
- Atrophic Vaginitis, Atrophy, Vaginitis
- Trial name
- NCT00137371
- Testing
- PVC (daily for 21 days, 7 days off), PVC (twice weekly)
- Where
- 49 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Menopause, Estrogen Deficiency
ATENEA Study: Adherence to Creatine-Based Nutritional Supplementation in Estrogen-Depleted Women
This is a prospective, multicenter, observational clinical study conducted under routine clinical practice conditions aimed at describing adherence to a creatine-based nutritional supplement (Creaticare FEM) in estrogen-depleted…
- Trial name
- ATENEA (NCT07580846)
- Where
- 4 sites in Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Margan Biotech
Advanced Metastatic Breast Cancer
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
- Trial name
- NCT01597388
- Testing
- AZD2014, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen